In May, I wrote about how pharmaceutical companies were attempting to stop the FDA from banning the promotion of drugs for off-label uses. According to an Amarin press release issued on August 7, 2015, a United States District Court sided with the pharmaceutical company, saying that they “…may promote to healthcare professionals certain uses of Amarin’s lead product, Vascepa® (icosapent ethyl) capsules that are not covered by current FDA-approved labeling for the drug so long as the promotion is truthful and non-misleading.”
This is a huge win for life sciences companies that have evidence of drugs helping patients for unapproved uses. Naturally, it’s also a win for physicians and the patients they serve.
